Nomura Asset Management Co. Ltd. cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 46,359 shares of the medical equipment provider’s stock after selling 1,124 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Hologic were worth $1,905,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Robeco Institutional Asset Management B.V. boosted its holdings in Hologic by 92.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 22,272 shares of the medical equipment provider’s stock worth $913,000 after buying an additional 10,722 shares in the last quarter. Stratos Wealth Partners LTD. acquired a new position in Hologic during the third quarter worth about $185,000. Bessemer Group Inc. raised its position in Hologic by 122.4% during the third quarter. Bessemer Group Inc. now owns 3,534 shares of the medical equipment provider’s stock worth $145,000 after acquiring an additional 1,945 shares during the last quarter. LSV Asset Management acquired a new position in Hologic during the third quarter worth about $1,319,000. Finally, SG Americas Securities LLC raised its position in Hologic by 167.8% during the third quarter. SG Americas Securities LLC now owns 93,708 shares of the medical equipment provider’s stock worth $3,840,000 after acquiring an additional 58,717 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.
HOLX has been the subject of a number of analyst reports. Morgan Stanley lowered shares of Hologic from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $44.00 to $39.00 in a research report on Wednesday, January 2nd. Canaccord Genuity restated a “hold” rating and issued a $41.00 target price on shares of Hologic in a report on Monday, January 7th. Needham & Company LLC restated a “buy” rating and issued a $48.00 target price on shares of Hologic in a report on Monday, January 14th. BidaskClub upgraded shares of Hologic from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 21st. Finally, Piper Jaffray Companies boosted their target price on shares of Hologic to $49.00 and gave the company an “overweight” rating in a report on Thursday, January 31st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $44.52.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.01. The business had revenue of $830.70 million during the quarter, compared to the consensus estimate of $823.22 million. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.55 earnings per share. On average, research analysts predict that Hologic, Inc. will post 2.41 EPS for the current year.
In other news, insider Peter J. Valenti III sold 4,242 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $47.38, for a total value of $200,985.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin Jordan Cohn sold 6,830 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $46.70, for a total transaction of $318,961.00. Following the completion of the transaction, the insider now owns 22,002 shares of the company’s stock, valued at $1,027,493.40. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://dakotafinancialnews.com/2019/03/15/hologic-inc-holx-shares-sold-by-nomura-asset-management-co-ltd.html.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: How To Calculate Debt-to-Equity Ratio
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.